Quantcast
Last updated on April 18, 2014 at 8:37 EDT

Latest Oncolytic virus Stories

2013-03-05 08:28:09

CALGARY, March 5, 2013 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC) (NASDAQ:ONCY) today announced that it has completed patient enrollment in a Phase 2 clinical trial evaluating intravenous administration of REOLYSIN(®) in combination with paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC) with Kras or EGFR-activated tumours (REO 016). This trial is a single arm, single-stage, open-label, Phase 2 study of REOLYSIN given intravenously...

2013-02-25 16:26:59

CALGARY, Feb. 25, 2013 /PRNewswire/ - Dr. Matt Coffey, Chief Operating Officer of Oncolytics Biotech Inc. (TSX: ONC) (NASDAQ: ONCY), will present at the 2013 RBC Capital Markets Healthcare Conference on Tuesday, February 26, 2013 at 3:35 p.m. ET. The conference will take place on February 26(th) and 27(th) in New York, NY. A live audio link to the webcast presentation is available at: http://www.veracast.com/webcasts/rbc/healthcare2013/71114328.cfm or on the company's website at...

2013-02-20 16:26:11

CALGARY, Feb. 20, 2013 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics" or the "Company") (TSX: ONC, NASDAQ: ONCY) today announced the appointment of Dr. Jeremy Grushcow to the role of General Counsel. Dr. Grushcow has more than ten years' experience in the legal profession representing public and private entities, as well as venture capital and private equity firms in the acquisition, financing, development, operation and sale of pharmaceutical and life sciences companies in...

2013-02-08 08:25:13

CALGARY, Feb. 8, 2013 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX: ONC) (NASDAQ: ONCY) today announced results examining percent overall tumour shrinkage data from its U.S. Phase 2 clinical trial in patients with squamous cell carcinoma of the lung (SCCLC) using intravenous administration of REOLYSIN(®) in combination with carboplatin and paclitaxel (REO 021). The analysis examined percent best overall tumour changes between pre-treatment and up to six treatment...

2013-02-01 09:50:46

A genetically reprogrammed Herpes simplex virus (HSV) can cure metastatic diffusion of human cancer cells in the abdomen of laboratory mice, according to a new study published January 31 in the Open Access journal PLOS Pathogens. The paper reports on the collaborative research from scientists at the at the University of Bologna and specifically describes that the HSV converted into a therapeutic anticancer agent attacks breast and ovarian cancer metastases. Past decades have witnessed...

2013-01-28 08:28:15

CALGARY, Jan. 28, 2013 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced a poster presentation covering positive preliminary results from a Phase I study examining the intravenous administration of REOLYSIN in combination with FOLFIRI in patients with metastatic colorectal cancer (REO 022). The results were presented at the ASCO Gastrointestinal Cancers Symposium in San Francisco, CA, which took place from January 24-26, 2013. The poster...

2013-01-22 08:30:59

AMSTERDAM, January 22, 2013 /PRNewswire/ -- uniQure B.V., the leader in the field of human gene therapy, today announced the appointment of Philip Astley-Sparke, former President and CEO of BioVex, as President US to provide strategic leadership and help build uniQure's clinical, regulatory, and commercial infrastructure in the US. Since May 2012, Philip is a venture partner at Forbion Capital Partners, uniQure's largest investor. As a venture partner he works with...

2012-12-13 08:26:03

CALGARY, Dec. 13, 2012 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics" or the "Company") (TSX: ONC) (NASDAQ: ONCY) today announced initial positive top line data from the first endpoint in its double-blinded randomized Phase III clinical study examining REOLYSIN in combination with carboplatin and paclitaxel in second-line patients with platinum-refractory, taxane-naïve head and neck cancers (REO 018). The endpoint examines initial percentage tumour changes between...

2012-11-26 11:21:26

-People with a type of brain tumor called glioblastoma live 12 months on average, so new forms of treatment for this malignancy are badly needed. -Viruses designed to kill cancer cells offer a safe way to treat these tumors, but the therapy doesn't work as well as expected. -This study found that a patient's immune system tries to eliminate the anticancer virus and blocking this immune activity gave the virus more time to kill cancer cells. Doctors now use cancer-killing viruses to treat...

2012-11-12 08:26:42

CALGARY, Nov. 12, 2012 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics" or the "Company") (TSX:ONC, NASDAQ:ONCY) today announced the appointment of Mr. Kirk Look to the role of Chief Financial Officer. Mr. Look has served as Oncolytics' Controller since 2003 and has been the Chief Financial Officer of Oncolytics Biotech (U.S.) Inc. since 2009. Prior to joining Oncolytics, Mr. Look held progressively senior audit roles with Ernst & Young LLP in both North and South America...